Literature DB >> 2720708

Influence of low doses of an oxazaphosphorine on natural killer activity of human lymphocytes.

H Blomgren1.   

Abstract

The influence of cis-4-sulfoethylthio-cyclophosphamide (mafosfamide) on natural killer cell activity was examined in vitro in order further to elucidate the possible immunological mechanisms of tumor regressions following low-dose oxazaphosphorine therapy. It was observed that cytotoxicity of human blood lymphoid cells was unchanged or reduced when the lymphocytes were pretreated for 24 h with mafosfamide or when the drug was present during incubation with K562 cells. However, when lymphoid cells were preincubated with human leukocyte interferon plus mafosfamide, natural killer activity was enhanced above the level caused by interferon alone. This enhancement was noted at mafosfamide concentrations of 1 nM-1 microM and was only present when the lymphocyte preparation was contaminated with monocytes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2720708     DOI: 10.1007/BF00199291

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  12 in total

1.  Elimination of immune suppressor mechanisms in humans by oxazaphosphorines.

Authors:  D Berd; M J Mastrangelo
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-09

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

Review 3.  Oxazaphosphorines as biological response modifiers--experimental and clinical perspectives.

Authors:  P Hilgard; J Pohl; J Stekar; R Voegeli
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

Review 4.  Aspects of the experimental immunopharmacology of oxazaphosphorines.

Authors:  F Fazioli; M Sironi; A Vecchi; S Sozzani; F Spreafico
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-09

Review 5.  The MOPC-315 tumor as a model for the immunomodulatory effects of cyclophosphamide.

Authors:  M B Mokyr
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-09

Review 6.  Enhancement of the delayed-type hypersensitivity reaction by oxazaphosphorines.

Authors:  J L Turk
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-09

7.  Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.

Authors:  U Niemeyer; J Engel; G Scheffler; K Molge; D Sauerbier; W Weigert
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

8.  Oxazaphosphorine effects in L 5222 rat leukemia.

Authors:  J Pohl; T Reissmann; R Voegeli
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-09

9.  In vitro effects of 4-hydroxyperoxycyclophosphamide on human immunoregulatory T subset function.

Authors:  J J Smith; E Mihich; H Ozer
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-09

10.  Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis.

Authors:  G Trinchieri; D Santoli
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

View more
  2 in total

1.  Mafosfamide enhances interleukin-2-generated human effector cell cytotoxic activity against K562 myeloid leukaemia cells.

Authors:  H T Hassan
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

2.  Possible role of acrolein in oxazaphosphorine-induced enhancement of immunological reactivity.

Authors:  H Blomgren; M Hallström
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.